Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma(CLeAR) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 160 | Genentech, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07817901 | Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma | not yet recruiting | Phase 1 / Phase 2 | 46 | Yonsei UniversityOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 204 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819188 | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02772003 | DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | active not recruiting | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT04162015 | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | active not recruiting | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04571138 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 35 | Seattle Children's HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT04923126 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | recruiting | Phase 1 / Phase 2 | 132 | St. Jude Children's Research HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04972942 | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma(ALLO-T-DART) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 49 | GenmabINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05300282 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients(FIL_A-BEGEV) | active not recruiting | Phase 1 / Phase 2 | 122 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | recruiting | Phase 1 | 398 | Astellas Pharma Global Development, Inc.INDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT05470283 | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | active not recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 70 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05630794 | Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05640193 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05641259 | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | recruiting | Phase 1 | 198 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 342 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06083857 | PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 112 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | BeOne MedicinesINDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II) | suspended | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06830031 | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma(C402) | recruiting | Phase 1 | 18 | Shanghai Exuma Biotechnology Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Elizabeth Stover, MD, PhDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 154 | Debiopharm International SAINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07022964 | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | recruiting | Phase 1 | 56 | CerenomeINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07087002 | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | recruiting | Phase 1 | 18 | Stanford UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 33 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07132541 | Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)(NBCA) | recruiting | Phase 1 | 30 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | suspended | Phase 1 | 90 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | recruiting | Phase 1 / Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | not yet recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 17 days agoSource updated Sep 14, 2026source: clinicaltrials